Scientific Advisory Board

Roland Wandeler, MSc, PhD

• 15+ years commercial leadership & general management in pharma & biotech
• Former Amgen GM Germany/Spain/Portugal; CVP & GM, US Bone Health & Cardiology
• MSc & PhD – Chemical Engineering – ETH Zurich

Wayne Paterson

• Director & CEO, Anteris Technologies Ltd
• Leadership roles at Roche (Korea/China) and Merck KGaA (Global CV Medicine, 2010–2012)

Jay Horton, MD

• Pioneer in PCSK9 characterization and LDL-R interactions
• Professor of Internal Medicine & Molecular Genetics; Chief, Digestive & Liver Diseases, UT Southwestern

Tomi Sawyer, PhD

• Inventor: NDP‑MSH (Scenesse®), ALRN‑6924 (Aileron), Iclusig® (Ariad/Takeda)
• Former Distinguished Scientist (Merck), CSO (Aileron), SVP (Ariad), Sr. Director (Pfizer)

Nabil G. Seidah, MC, PhD, OQ, PRSC

• Discovered & cloned seven of nine proprotein convertases including PCSK9
• Author of 720+ peer‑reviewed articles; numerous prestigious awards

Michael D. Shapiro, DO

• Professor of Cardiology & Molecular Medicine, Wake Forest University
• Research in atherosclerosis imaging, lipid disorders, PCSK9 physiology

Nicola Ferri, PhD

• Professor of Pharmacology, University of Padua
• Author of 190+ peer‑reviewed articles; ‘Emerging oral therapeutic strategies for inhibiting PCSK9’

Ajoy Basak, MSc, PhD, FIC

• Inventor of AQR‑008; 25+ years in PCSK9 & cholesterol research
• Adjunct Professor, University of Ottawa; Affiliate Investigator, Ottawa Hospital Research Institute

David M. Lubman, PhD

• Professor Emeritus, University of Michigan Medical School; Director, The Lubman Lab
• MS – Columbia University; PhD – Stanford University

Bruce Auerbach, MS

• 20+ years in pharma discovery & early clinical development; former Associate Research Fellow, Pfizer
• Focus on dyslipidemia & metabolic diseases

Mary G. Sorci-Thomas, PhD

• Professor of Medicine, Medical College of Wisconsin (Endocrinology, Metabolism & Clinical Nutrition)
• NIH-funded 33+ years; Project Leader on NIH Program Project studying Atherosclerosis & Lipid Metabolism

Robert E. Burrier, PhD

• Career technology executive in pharma research; contributed to Zetia & Vytorin programs
• Experience at Schering‑Plough, Merck KGaA, Eli Lilly, GelTex, Genzyme; Postdoc – Wake Forest University

David M. Filsoof, MD

• Medical Director, Beverly Hills Cardiovascular; fellowship at Mayo Clinic
• 10+ years at Cedars‑Sinai; BA – Emory; MD – New York Medical College

Khaled Machaca, PhD

• Senior Associate Dean for Research, Innovation & Commercialization, Weill Cornell Medicine‑Qatar
• Lab focuses: Ca²⁺ signaling, non‑genomic progesterone signaling, personalized medicine for monogenic disorders

George M. Tsoukas, MD

• Associate Professor of Medicine, McGill University Health Centre
• Expert in endocrinology & cardiovascular disease; FRCP(C)